A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis

Current therapies for anthrax include the use of antibiotics (i.e., doxycycline, and ciprofloxacin), an anthrax vaccine (BioThrax) and Bacillus anthracis-specific, monoclonal antibody (mAb) (i.e., Raxibacumab and obiltoxaximab). In this study, we investigated the activity of immunomodulators, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Chih-Yuan, Lane, Douglas J., Zou, Yefen, Hoffman, Tim, Pan, Jianfeng, Hampton, Janice, Maginnis, Jillian, Nayak, Bishnu P., D’Oro, Ugo, Valiante, Nicholas, Miller, Andrew T., Cooke, Michael, Wu, Tom, Bavari, Sina, Panchal, Rekha G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965344/
https://www.ncbi.nlm.nih.gov/pubmed/35369443
http://dx.doi.org/10.3389/fmicb.2022.803041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965344/
https://www.ncbi.nlm.nih.gov/pubmed/35369443
http://dx.doi.org/10.3389/fmicb.2022.803041

Ejemplares similares